glp-1 receptor antagonist agonists in the treatment of type 2 diabetes – state-of-the-art Complementary Yet Distinct Roles of

Personalization of Treatment to BMI and ORC Patient heterogeneity, including metabolically obese normal weight (MONW) individuals, patients with severe obesity (BMI 40), and sarcopenic elderly populations poses challenges for standardized interventions

Patients with Cardiovascular Risk Factors: Research suggests that GLP1 receptor agonists may provide cardiovascular benefits, including reduced risk of heart attack and stroke in patients with type 2 diabetes

Then continue correcting the remaining deficit via IV if needed, with less risk of arrhythmias

The latter enters the territory of sterile compounding, which carries distinct regulatory requirements a standard clinical environment is not designed to meet